Biomarkers of Exposure among U.S. Adult Cigar Smokers: Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013-2014).
Adolescent
Adult
Biomarkers
/ urine
Carcinogens
/ analysis
Cotinine
/ urine
Environmental Exposure
/ adverse effects
Female
Follow-Up Studies
Humans
Male
Middle Aged
Nicotine
/ adverse effects
Nitrosamines
/ urine
Prognosis
Smoking
/ adverse effects
Tobacco Products
/ adverse effects
United States
/ epidemiology
Young Adult
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
15
05
2018
revised:
09
08
2018
accepted:
30
01
2019
pubmed:
9
2
2019
medline:
17
7
2020
entrez:
9
2
2019
Statut:
ppublish
Résumé
Given the diverse cigar market and limited data on biomarker patterns by cigar type, we compared biomarkers of nicotine and tobacco toxicants among cigar smokers and other groups. Using Wave 1 urinary biomarker data from 5,604 adults in the Population Assessment of Tobacco and Health (PATH) Study, we compared geometric mean concentrations among cigar-only smokers (all cigars and separately for traditional, cigarillo, and filtered cigars), cigarette-only smokers, dual cigar/cigarette smokers, and never users of tobacco. We calculated geometric mean ratios comparing groups with never users adjusting for sex, age, race/ethnicity, education and creatinine. Some day cigar-only smokers had lower biomarker concentrations than every day cigar-only smokers, but higher than never users. Every day cigar-only smokers ( For some biomarkers, every day cigar-only smokers were comparable with every day cigarette-only smokers. Exploratory analyses suggest that biomarkers vary by cigar type with every day filtered cigar-only smokers having the highest concentrations. High exposure to harmful constituents among cigar smokers is a continuing health issue.
Sections du résumé
BACKGROUND
Given the diverse cigar market and limited data on biomarker patterns by cigar type, we compared biomarkers of nicotine and tobacco toxicants among cigar smokers and other groups.
METHODS
Using Wave 1 urinary biomarker data from 5,604 adults in the Population Assessment of Tobacco and Health (PATH) Study, we compared geometric mean concentrations among cigar-only smokers (all cigars and separately for traditional, cigarillo, and filtered cigars), cigarette-only smokers, dual cigar/cigarette smokers, and never users of tobacco. We calculated geometric mean ratios comparing groups with never users adjusting for sex, age, race/ethnicity, education and creatinine.
RESULTS
Some day cigar-only smokers had lower biomarker concentrations than every day cigar-only smokers, but higher than never users. Every day cigar-only smokers (
CONCLUSIONS
For some biomarkers, every day cigar-only smokers were comparable with every day cigarette-only smokers. Exploratory analyses suggest that biomarkers vary by cigar type with every day filtered cigar-only smokers having the highest concentrations.
IMPACT
High exposure to harmful constituents among cigar smokers is a continuing health issue.
Identifiants
pubmed: 30733305
pii: 1055-9965.EPI-18-0539
doi: 10.1158/1055-9965.EPI-18-0539
pmc: PMC6500461
mid: NIHMS1520976
doi:
Substances chimiques
Biomarkers
0
Carcinogens
0
Nitrosamines
0
Nicotine
6M3C89ZY6R
Cotinine
K5161X06LL
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
943-953Subventions
Organisme : Intramural FDA HHS
ID : FD999999
Pays : United States
Organisme : NIDA NIH HHS
ID : HHSN271201100027C
Pays : United States
Organisme : NIDA NIH HHS
ID : HHSN271201600001C
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Nicotine Tob Res. 2016 Apr;18(4):460-9
pubmed: 25782456
Pharmacogenet Genomics. 2016 Jul;26(7):340-50
pubmed: 27035242
Chem Res Toxicol. 2010 Jun 21;23(6):1001-8
pubmed: 20408564
Nicotine Tob Res. 2011 Sep;13(9):874-9
pubmed: 21504888
Nicotine Tob Res. 2018 Nov 15;20(12):1457-1466
pubmed: 29059423
Chest. 1979 Feb;75(2):136-40
pubmed: 421548
J Pharmacol Exp Ther. 1999 Dec;291(3):1196-203
pubmed: 10565842
Am J Hypertens. 2004 Apr;17(4):299-303
pubmed: 15062882
Tob Control. 2017 May;26(3):349-354
pubmed: 27220622
Occup Environ Med. 1998 Dec;55(12):834-9
pubmed: 9924445
Tob Induc Dis. 2016 Aug 18;14:29
pubmed: 27547175
Tob Control. 2017 May;26(3):269-276
pubmed: 27122063
MMWR Morb Mortal Wkly Rep. 2017 Nov 10;66(44):1209-1215
pubmed: 29121001
Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):291-302
pubmed: 28151705
Tob Regul Sci. 2017 Apr;3(Suppl 1):S72-S83
pubmed: 28966952
Cancer Res. 1979 Jul;39(7 Pt 1):2505-9
pubmed: 445452
N Engl J Med. 2015 Oct;373(14):1340-9
pubmed: 26422724
Lung Cancer. 2006 Oct;54(1):11-8
pubmed: 16884817
Pharmacol Biochem Behav. 2015 Dec;139(Pt A):7-14
pubmed: 26459155
Br Med J. 1977 Nov 26;2(6099):1387-9
pubmed: 589225
Am Ind Hyg Assoc J. 1993 Oct;54(10):615-27
pubmed: 8237794
Eur Heart J. 2005 Sep;26(17):1765-73
pubmed: 15817606
Tob Regul Sci. 2018 Jan;4(1):548-561
pubmed: 29516029
JAMA. 1985 Dec 20;254(23):3330-2
pubmed: 4068167
Nicotine Tob Res. 2018 Jan 5;20(2):183-191
pubmed: 27798089
Nicotine Tob Res. 2012 Mar;14(3):368-71
pubmed: 22025543
Clin Pharmacol Ther. 1978 Feb;23(2):143-51
pubmed: 620474
Ann Intern Med. 2010 Feb 16;152(4):201-10
pubmed: 20157134
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2906-15
pubmed: 25380733
Tob Regul Sci. 2017 Oct;3(4):459-478
pubmed: 29911130
Am J Public Health. 1999 May;89(5):731-6
pubmed: 10224986
BMC Public Health. 2015 Apr 24;15:390
pubmed: 25907101
Am J Public Health. 2014 Sep;104(9):e86-91
pubmed: 25033140